Bifogade filer
Kurs
-2,00%
Likviditet
2,89 MSEK
Kalender
Tid* | ||
2026-02-05 | 08:30 | Bokslutskommuniké 2025 |
2025-11-13 | 08:30 | Kvartalsrapport 2025-Q3 |
2025-08-21 | 08:30 | Kvartalsrapport 2025-Q2 |
2025-05-30 | N/A | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2025-05-28 | N/A | Årsstämma |
2025-05-15 | 08:30 | Kvartalsrapport 2025-Q1 |
2025-02-06 | - | Bokslutskommuniké 2024 |
2024-11-14 | - | Kvartalsrapport 2024-Q3 |
2024-10-30 | - | Split EXPRS2 40:1 |
2024-08-15 | - | Kvartalsrapport 2024-Q2 |
2024-06-07 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2024-06-05 | - | Årsstämma |
2024-05-16 | - | Kvartalsrapport 2024-Q1 |
2024-02-08 | - | Bokslutskommuniké 2023 |
2023-11-16 | - | Kvartalsrapport 2023-Q3 |
2023-08-17 | - | Kvartalsrapport 2023-Q2 |
2023-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2023-05-24 | - | Årsstämma |
2023-05-16 | - | Kvartalsrapport 2023-Q1 |
2023-03-23 | - | Extra Bolagsstämma 2023 |
2023-02-09 | - | Bokslutskommuniké 2022 |
2022-11-17 | - | Kvartalsrapport 2022-Q3 |
2022-08-18 | - | Kvartalsrapport 2022-Q2 |
2022-05-31 | - | Kvartalsrapport 2022-Q1 |
2022-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2022-05-25 | - | Årsstämma |
2022-02-24 | - | Bokslutskommuniké 2021 |
2021-11-18 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2021-05-26 | - | Årsstämma |
2021-05-19 | - | Kvartalsrapport 2021-Q1 |
2021-02-25 | - | Bokslutskommuniké 2020 |
2020-11-19 | - | Kvartalsrapport 2020-Q3 |
2020-09-23 | - | Extra Bolagsstämma 2020 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2020-05-26 | - | Årsstämma |
2020-05-20 | - | Kvartalsrapport 2020-Q1 |
2020-02-28 | - | Bokslutskommuniké 2019 |
2019-11-14 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-24 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2019-05-23 | - | Årsstämma |
2019-05-16 | - | Kvartalsrapport 2019-Q1 |
2019-02-28 | - | Bokslutskommuniké 2018 |
2018-11-22 | - | Kvartalsrapport 2018-Q3 |
2018-08-24 | - | Kvartalsrapport 2018-Q2 |
2018-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2018-05-24 | - | Årsstämma |
2018-05-17 | - | Kvartalsrapport 2018-Q1 |
2018-02-07 | - | Bokslutskommuniké 2017 |
2017-11-30 | - | Kvartalsrapport 2017-Q3 |
2017-08-31 | - | Kvartalsrapport 2017-Q2 |
2017-06-01 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2017-05-31 | - | Årsstämma |
2017-05-24 | - | Kvartalsrapport 2017-Q1 |
2017-04-19 | - | Extra Bolagsstämma 2017 |
2017-02-28 | - | Bokslutskommuniké 2016 |
2016-11-08 | - | Kvartalsrapport 2016-Q3 |
2016-08-31 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, April 7, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include the World Vaccine Congress (April 18-21), a Q&A session covering the 2022 Rights Issue (April 25), Økonomisk Ugebrev Life Science Investor Conference (April 27), PEGS Summit (May 2-6), and the ESMO Breast Cancer Meeting (May 3-5).
By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS[2] technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below.
World Vaccine Congress, April 18-21
Washington, D.C., USA
Meet in-person with ExpreS[2]ion's CMO, Mattis Flyvholm Ranthe at the largest, most established meeting dedicated to vaccines. More information and registration can be found on the World Vaccine Congress website (https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm).
2022 Rights Issue Q&A hosted by H.C. Andersen Capital, April 25 at 11:00 CET
Virtual
ExpreS[2]ion CEO Bent U. Frandsen and CFO Keith Alexander will discuss the 2022 Rights Issue and answer investor's questions about how to participate. More information and registration can be found on the H.C. Andersen Capital events website (https://hcandersencapital.dk/events/) closer to the webcast.
Økonomisk Ugebrev Life Science Investor Conference, April 27 at 15:50-16:20 CET
Copenhagen, Denmark
See the company presentation by our CEO Bent U. Frandsen at this investor event. It is possible to attend the meeting by reserving a seat on the event website (https://www.eventbrite.co.uk/e/life-science-investor-konference-den-27-april-2022-tickets-296710217247?aff=odeimcmailchimp&utm_source=Marketing&utm_campaign=bb056e5d1f-EMAIL_CAMPAIGN_2019_08_20_07_22_COPY_01&utm_medium=email&utm_term=0_32a4ba3d31-bb056e5d1f-108505633&mc_cid=bb056e5d1f&mc_eid=f12ce3e69b).
PEGS Summit, May 2-6
Boston, MA, USA
Meet virtually with ExpreS[2]ion's VP of R&D and Technology, Max Søgaard, at the leading international meeting for the biotherapeutics community. More information and registration can be found on the PEGS Summit website (https://www.pegsummit.com/).
European Society for Medical Oncology (ESMO) Breast Cancer Meeting, May 3-5
Berlin, Germany and Virtual
Meet with ExpreS[2]ion's CMO, Mattis Flyvholm Ranthe, and VP of Preclinical Development, Mette Thorn, at 2022 ESMO Breast Cancer meeting. More information and registration can be found on the ESMO website (https://www.esmo.org/meetings/esmo-breast-cancer-2022).
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com